Meet Antonio Capone, Jr., MD, and His Pioneering Work in Face-Down Positioning after Macular Hole Surgery
by Maureen Duffy
Antonio Capone, Jr., M.D. is a board-certified ophthalmologist whose special interests include pediatric vitreoretinal diseases, complicated retinal detachment, ocular oncology, and macular disease.
Dr. Capone is an internationally recognized clinician, surgeon, and educator. He has authored or co-authored over 200 publications in peer-reviewed medical journals, book chapters, and publications from clinical trials. He is currently a Professor of Biomedical Sciences at Oakland University, and Professor at the European School for Advanced Studies in Ophthalmology, Lugano, Switzerland.
In addition, he is Co-Director of the Vision Research-ROPARD Foundation, overseeing the Foundation's clinical research initiative at Associated Retinal Consultants throughout Michigan. Dr. Capone has been named to America's Who's Who in Medicine, The Best Doctors in America, The Best Doctors in the Southeast, and Hour Detroit Magazine's Top Docs. He serves on the Executive Committee of the American Society of Retina Specialists and The Retina Society.
Maureen Duffy: Hello Doctor Capone. It's an honor to speak with you. To begin, can you tell us more about your background, education, and your professional specialty? How (and when) did you decide to become a retinal surgeon?
Antonio Capone: I'm honored that you asked. My parents immigrated to the states from Italy in the mid-1950s. I grew up in New England and went to undergraduate and medical school at Brown University. I did my residency in ophthalmology at the University of Pittsburgh, and a Fellowship in Vitreoretinal Diseases and Surgery at Emory University in Atlanta.
I remembered very clearly when I decided to be a doctor: I was in the third grade. My dad was a psychiatrist and someone came up to me while I was in school, speaking about my father in such glowing terms that it made a big impression on me. I aspired to be the type of man whom folks would one day see in a similar light.
I started out in a psychiatry residency, anticipating that I would finish my training and work with my father. As it happened, the work was incredibly interesting intellectually, but the day-to-day practice of psychiatry wasn't a good match for me temperamentally. The other experiences I had in medical school which were attractive to me as a specialty were surgical subspecialties. The meticulous precision of eye surgery appealed to me and proved to be a much better match for my temperament.
I did a pre-residency research fellowship in cornea, and went through my residency thinking I would want to be an orbital [i.e., having to do with the eye socket] surgeon. Once I did my retina rotation during residency, however, I found the career path I'd been looking for. On a personal level it is highly impactful and incredibly gratifying work. Intellectually, I knew the vast majority of discoveries with regard to understanding retinal disease and novel therapies were yet to be explained and analyzed; therefore, it was an endeavor that would be intellectually stimulating for my entire professional career.
MD: One of the most-visited pages on the VisionAware website is our five-part first-person series on Surviving Recovery from Macular Hole Surgery by Joy R. Efron, Ed.D., which includes Suggestions for Maintaining Face-Down Positioning. Your research, however, indicates that face-down positioning is not required for a successful outcome. Can you share the highlights of your research with our readers?
AC: Macular hole surgery has an interesting, and fairly recent, evolution and history. In the late 1980s-early 1990s, macular hole was a diagnosis for which there was no surgical intervention. Kelly and Wendel, two retinal surgeons from northern California, first sought to operate on folks with macular hole and demonstrated that they could be successfully closed in some patients with subsequent improvement in vision. Interestingly, this was a controversial topic at that time, as many patients with macular hole are affected in only one eye, and both before and after surgery the better eye is the unoperated eye.
The "pros/cons of repair" controversy was followed by a debate as to whether it was safe to remove an intrinsic inner layer of the retina known as the internal limiting membrane (ILM). Up until then, only a thin layers of scar tissue which grew on the retinal surface (epiretinal membrane, or macular "pucker") was ever removed surgically. Taking off scar tissue is something that sounds logical. Removing an intrinsic layer of the retina itself seemed counter-intuitive. This too was controversial at the time. Doing so seemed to improve outcomes (meaning the percent of eyes with successfully closed holes).
The opposing school of thought was that while macular holes may be closed more effectively by removing the ILM, removal of an inner layer of the retina itself couldn't help but be detrimental in the long run. As it turns out, this latter concern has proven unfounded. Removing ILM in most surgeons' hands improves the success rate in macular hole surgery from 70%-80% to 90-95%.
The other big controversy related to the issue of face-down positioning. In the early 1990s, some surgeons asked patients to lie face down for up to a month after surgery. Little by little, as my success rate in macular hole closure improved, I started to whittle away at the duration of face-down positioning. This was the aspect of surgery that many people hated the most and I became less and less convinced that it was imperative for success. Over the years, I went from a week of face-down positioning, to three days of face-down positioning, to overnight positioning.
MD: What was your "hunch" or "instinct" that led to your initial decision to use a one-day recovery period after macular hole surgery? You first used this technique in 2001, correct?
AC: Yes – Since 2001, I've been down to as little as overnight face-down positioning on the day of surgery only. There were two main drivers to the decision to do short-duration positioning. First, my personal results were as good as anyone else's – irrespective of duration of positioning. That led me to the notion that it wasn't the positioning that was most important, but the ILM peeling described above.
Second, data started to come to publication that macular hole closure could be demonstrated within 24 hours of surgery, using an imaging technology known as optical coherence tomography (OCT). [Editor's note: OCT is a type of medical imaging technology that produces high-resolution cross-sectional and three-dimensional images of the eye.]
We published our results on the one day of face-down positioning, entitled Surgical outcomes of idiopathic macular hole repair with limited postoperative positioning, which were as good as the results published by anyone else. Currently, I don't require face-down positioning at all for typical macular holes.
MD: I'm interested to know your thoughts about many of the great strides that have been made during the past ten years in eye care, especially with the early, yet positive, results from stem cell clinical trials for Stargardt disease and dry macular degeneration and gene therapy for retinal disease.
AC: Stem cell therapy is an interesting topic. The notion of stem cell therapy is very attractive. The idea that you can take a so-called pleuri-potential cell, which has the theoretical capacity to become any cell that is needed and be normal in structure and function, and place that cell anywhere in the body is extremely attractive.
Conversely, the scientific reality with regards to stem cell therapy is nowhere near as advanced as this notion. A good analogy would be taking a wrench and throwing it at a car with an engine problem, and hoping that the wrench is going to somehow know how to fix the car. Unsurprisingly, the early days of stem cell therapy, and I don't think we are far from that now, have been fraught with stops and starts, high expectation, and frequent disappointment.
All of that said, it is an incredibly promising therapy. However, stem cell therapy becoming a reality is something that will happen in small methodical steps, as is typically the case in scientific endeavor. While there is clearly a role for stem cell therapy in the management of hereditary and degenerative diseases, there is yet a long piece of road before that role is realized. That we are in a day and time when stem cell clinical trials are ongoing is very exciting. However, I think this work is still in its infancy.
Gene therapy has similar appeal, as our understanding of disease increasingly demonstrates a genetic/molecular basis. The notion of fixing cells with the wrong genetics by inserting the right genetics again has appeal by virtue of its simplicity. And again, the reality is a bit more daunting, but this approach has incredible promise. Also, the technology is also in the clinical trial phase, which generally means approximately 2-6 years prior to implementation in routine clinical care.
MD: What do you regard as the next great frontier in ophthalmology or vision science in general?
AC: For all of medicine, understanding the molecular basis of a disease is the linchpin for the development of effective therapeutic interventions. For example, right now we have very effective therapies directed against vascular endothelial growth factor, the overproduction of which is important in a number of clinical conditions. [Editor's note: When used in the context of ophthalmology, vascular endothelial growth factor, or VEGF, is a protein that stimulates abnormal blood vessel growth in the retina and macula.] After understanding the molecular mechanism of a disease, delivering the drug therapy in a fashion that is durable is the next big step, typically then taking 2-5 years to get to clinical trials.
Once we unravel the therapeutic riddles leading to new effective therapies, the next challenge is drug delivery. I'd expect big strides in the next 5-10 years in this area of research as well. The time when a disease with a specific molecular fix can be treated with a sustained delivery approach will be soon upon us. It's a very exciting time for research into diseases of the retina and vitreous.
We thank Dr. Antonio Capone for his support of VisionAware and for his longstanding research and practice on behalf of blind and visually persons worldwide. It has been a privilege to speak with you.
Re: Meet Antonio Capone, Jr., MD, and His Pioneering Work in Face-Down Positioning after Macular Hole SurgeryPosted by bryangerritsen on 9/9/2015 at 11:50 AM
Thank you, Maureen, for this excellent and helpful interview with Dr. Capone, and in particular, his important work with the internal limiting membrane (ILM) for macular hole surgery. It's interesting to work with patients now that have little or absolutely no "face down" time following macular hole surgery. I appreciate this interview that you did with him.
Bryan Gerritsen, CLVT
Re: Meet Antonio Capone, Jr., MD, and His Pioneering Work in Face-Down Positioning after Macular Hole SurgeryPosted by Sharala on 11/3/2015 at 7:06 PM
I would suggest a direct approach. Always best. Print out the article and send or deliver or email it to your doctor in advance of next appt and say you would like to discuss. Background: I had this procedure for macular hole in 2008. The hole reopened this summer (because i didn't have the ILM peeling.) The first surgery I was 7 days face down. It was doable,but not fun. had perfect recovery 20/25! I had my second vitrectomy yesterday with different surgeon, partner of Dr. Capone. He gave me three days plus can sleep on R ear. I saw Dr, Capone for post op visit today. At that time i had not read this article about him. Found it by lucky coincidence, tonight. My take on this is age and training of doctors. Differing opinions. If you need to do face down highly recommend renting equipment. US supplier I used is Owl. oak leasing. Chair and bed support most useful. I am short so travel block and table support not helpful. Good luck! You can do whatever is required!!!
Log in to Post a Comment
- Low Vision (247 posts)
- Medical Updates (179 posts)
- Macular Degeneration (119 posts)
- Clinical Trials (97 posts)
- In the News (96 posts)
- Diabetes and diabetic retinopathy (57 posts)
- Glaucoma (69 posts)
- Health (51 posts)
- Cataracts (32 posts)
- Lucentis (25 posts)
- Avastin (23 posts)
- Eylea (16 posts)
- Personal Reflections (95 posts)
- Social Life and Recreation (35 posts)
- Cultural Diversity (30 posts)
- Updates from the London Project to Cure Blindness: Stem Cell Research for Wet and Dry Macular Degeneration
- New Research Examines the Association Between Diabetic Eye Disease and Depression: Should Eye Doctors Be More Alert to Patients' Mental Health?
- New Research Exploring Public Attitudes About Eye and Vision Health: Losing Vision Is Equal to Losing Hearing, Memory, Speech, or a Limb